Siamo certi che tutti i pazienti con fibrillazione atriale e CHA2DS2-VASc score 1 debbano essere anticoagulati? | Giornale Italiano di Cardiologia - Organo ufficiale di Italian Federation of Cardiology e Società Italiana
![Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk](https://www.ahajournals.org/cms/asset/f0c76a4b-279a-46cf-abea-39dfbbb036a3/e003476fig02.jpeg)
Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk
![È sempre indicata una terapia anticoagulante orale in pazienti con Fibrillazione atriale e punteggio CHA2DS2-VASc 1? - ATBV È sempre indicata una terapia anticoagulante orale in pazienti con Fibrillazione atriale e punteggio CHA2DS2-VASc 1? - ATBV](https://atbv.it/wp-content/uploads/2016/01/PATTI-Chads-Vasc-F1.jpg)
È sempre indicata una terapia anticoagulante orale in pazienti con Fibrillazione atriale e punteggio CHA2DS2-VASc 1? - ATBV
![Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). - Abstract - Europe PMC Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). - Abstract - Europe PMC](https://europepmc.org/articles/PMC6708930/bin/medi-98-e16560-g002.jpg)
Predictive value of CHA2DS2-VASc scores regarding the risk of stroke and all-cause mortality in patients with atrial fibrillation (CONSORT compliant). - Abstract - Europe PMC
![Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation? | Journal of the American College of Cardiology Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation? | Journal of the American College of Cardiology](https://www.jacc.org/cms/asset/dff69616-31e9-406e-898a-e026864c053d/gr2.jpg)
Should Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation? | Journal of the American College of Cardiology
![JCM | Free Full-Text | Association of CHA2DS2-VASc Score with Long-Term Incidence of New-Onset Atrial Fibrillation and Ischemic Stroke after Myocardial Infarction JCM | Free Full-Text | Association of CHA2DS2-VASc Score with Long-Term Incidence of New-Onset Atrial Fibrillation and Ischemic Stroke after Myocardial Infarction](https://www.mdpi.com/jcm/jcm-11-07090/article_deploy/html/images/jcm-11-07090-g001.png)
JCM | Free Full-Text | Association of CHA2DS2-VASc Score with Long-Term Incidence of New-Onset Atrial Fibrillation and Ischemic Stroke after Myocardial Infarction
![CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease. - ppt download CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease. - ppt download](https://images.slideplayer.com/30/9547440/slides/slide_2.jpg)
CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease. - ppt download
![PDF] Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score | Semantic Scholar PDF] Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/701606b6f7d086fe6e65e93f9961d5ae9ad858bb/2-Table1-1.png)
PDF] Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score | Semantic Scholar
![Natural Changes in CHA2DS2-VASc Scores in Newly Diagnosed Non-valvular Atrial Fibrillation Patients with Low Stroke Risk - ISTH Congress Abstracts Natural Changes in CHA2DS2-VASc Scores in Newly Diagnosed Non-valvular Atrial Fibrillation Patients with Low Stroke Risk - ISTH Congress Abstracts](https://abstracts.isth.org/wp-content/uploads/2021/06/1080_results_1.png)
Natural Changes in CHA2DS2-VASc Scores in Newly Diagnosed Non-valvular Atrial Fibrillation Patients with Low Stroke Risk - ISTH Congress Abstracts
![PDF] Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. | Semantic Scholar PDF] Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/dd8fdb74de7e9a0a2ee3e916f24173b2cc49017a/2-Table1-1.png)
PDF] Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. | Semantic Scholar
![Table 2 from Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. | Semantic Scholar Table 2 from Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1a84262bf2416f30f2c400e67d530b3957f84ba5/3-Table2-1.png)
Table 2 from Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation. | Semantic Scholar
![Changes in CHA2DS2-VASc score and risk of ischemic stroke among patients with atrial fibrillation | Heart and Vessels Changes in CHA2DS2-VASc score and risk of ischemic stroke among patients with atrial fibrillation | Heart and Vessels](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00380-023-02278-1/MediaObjects/380_2023_2278_Fig5_HTML.png)